دورية
Positive Phase 3 Results for Novel Antipsychotic in Schizophrenia.
| العنوان: | Positive Phase 3 Results for Novel Antipsychotic in Schizophrenia. |
|---|---|
| المؤلفون: | Brooks, Megan |
| المصدر: | Clinical Psychiatry News; Jan2024, p29-29, 1p |
| مصطلحات موضوعية: | SCHIZOPHRENIA, DRUGS, MUSCARINIC receptors, MEDICAL research |
| مستخلص: | A recent study published in The Lancet has shown that a novel therapy called Xanomeline-trospium (KarXT) has led to significant improvements in positive and negative symptoms of schizophrenia compared to a placebo. The treatment was not associated with weight gain or severe side effects, and it works by activating muscarinic receptors rather than blocking dopamine receptors like current antipsychotic medications. The US Food and Drug Administration has accepted the company's new drug application for KarXT, and the results of the study suggest that it could be a promising alternative for patients with schizophrenia. However, more research is needed to determine its effectiveness compared to existing treatments. [Extracted from the article] |
| Copyright of Clinical Psychiatry News is the property of Frontline Medical Communications and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| قاعدة البيانات: | Complementary Index |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edb Complementary Index 175447954 915 6 Periodical serialPeriodical 915.496520996094 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=175447954&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edb&genre=article&issn=02706644&ISBN=&volume=&issue=&date=20240101&spage=29&pages=29-29&title=Clinical Psychiatry News&atitle=Positive%20Phase%203%20Results%20for%20Novel%20Antipsychotic%20in%20Schizophrenia.&id=DOI: [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Positive Phase 3 Results for Novel Antipsychotic in Schizophrenia.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Brooks%2C+Megan%22">Brooks, Megan</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Clinical Psychiatry News; Jan2024, p29-29, 1p ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22SCHIZOPHRENIA%22">SCHIZOPHRENIA</searchLink><br /><searchLink fieldCode="DE" term="%22DRUGS%22">DRUGS</searchLink><br /><searchLink fieldCode="DE" term="%22MUSCARINIC+receptors%22">MUSCARINIC receptors</searchLink><br /><searchLink fieldCode="DE" term="%22MEDICAL+research%22">MEDICAL research</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => A recent study published in The Lancet has shown that a novel therapy called Xanomeline-trospium (KarXT) has led to significant improvements in positive and negative symptoms of schizophrenia compared to a placebo. The treatment was not associated with weight gain or severe side effects, and it works by activating muscarinic receptors rather than blocking dopamine receptors like current antipsychotic medications. The US Food and Drug Administration has accepted the company's new drug application for KarXT, and the results of the study suggest that it could be a promising alternative for patients with schizophrenia. However, more research is needed to determine its effectiveness compared to existing treatments. [Extracted from the article] ) Array ( [Name] => Abstract [Label] => [Group] => Ab [Data] => <i>Copyright of Clinical Psychiatry News is the property of Frontline Medical Communications and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 1
[StartPage] => 29
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => SCHIZOPHRENIA
[Type] => general
)
[1] => Array
(
[SubjectFull] => DRUGS
[Type] => general
)
[2] => Array
(
[SubjectFull] => MUSCARINIC receptors
[Type] => general
)
[3] => Array
(
[SubjectFull] => MEDICAL research
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Positive Phase 3 Results for Novel Antipsychotic in Schizophrenia.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Brooks, Megan
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Text] => Jan2024
[Type] => published
[Y] => 2024
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 02706644
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Clinical Psychiatry News
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |